Author: cmyk

Life-cycle development Helsinn Group submits a new formulation of AKYNZEO® to the European Medicines Agency (EMA)

Partnership AnaCardio receives patent grant in Europe for AC01

Partnership Knight Therapeutics and Helsinn Healthcare SA expand relationship and enter into exclusive license, distribution, and supply agreement for Onicit®

Partnership Helsinn Group and ESTEVE sign a partnership agreement renewal to commercialize AKYNZEO® and ALOXI® in Germany

Partnership Helsinn attends EORTC annual meeting 2024 with a focus on Mycosis Fungoides Cutaneous T-cell Lymphoma (MF-CTCL)

News Helsinn Group appoints Riccardo Carbucicchio to the Board of Directors

Partnership Highlights of Helsinn’s attendance at ESMO 2023

News Helsinn attends ESMO Congress 2023 with a focus on cancer supportive care